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Background: Loop diuretic use is related to the severity of cardiac and renal dysfunction in chronic heart failure (HF). The association of discharge 
diuretic dose and outcomes in hospitalized HF (HHF) patients is less well studied.
methods: The Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial enrolled 4133 HHF patients with 
ejection fraction (EF) <40%. This analysis included 1313 patients assigned to the placebo arm and prescribed at least once daily oral loop diuretic 
at discharge. Weight-adjusted daily dose (WtDD) was calculated using furosemide-equivalent diuretic dose and discharge weight. Patients were 
followed for a median of 9.9 months for mortality and rehospitalization for HF.
results: The average WtDD was 1.09±1.13 mg/kg/day. Table 1 shows patients’ baseline characteristics and outcomes by WtDD quartiles. Patients 
in the highest WtDD quartile had lower EF, glomerular filtration rate, and blood pressure, and more often diabetes. After adjustment for 24 predictors 
of survival, higher WtDD was associated with an increased risk of all-cause mortality (hazard ratio [HR] Q4 vs Q1 1.78, 95% confidence interval [CI] 
1.25,2.55, P=0 .002) and cardiovascular mortality or rehospitalization for HF (HR Q4 vs Q1 1.36, 95% CI 1.04,1.77, P=0.023).
conclusion: Higher WtDD of diuretic at dicharge is independently associated with worse outcomes among HHF patients with reduced EF. Whether 
this signifies a risk marker or mediator relationship needs further study. 
Table 1. Baseline Characteristics and Outcomes of Patients According to WtDD of Diuretic
Variable (Mean±SD or percentage)
Quartile 1
N=328
Quartile 2
N=329
Quartile 3
N=328
Quartile 4
N=328
p-value
Weight-adjusted daily diuretic dose range (mg/kg/day) 0.017-0.494 0.496-0.790 0.791-1.277 1.278-16.484
Age (years) 62.9±11.8 66.1±11.1 66.1±12.5 66.3±13 <0.001
Ejection fraction (%) 29±7.5 27.7±7.9 25.8±8.1 25.4±7.8 <0.001
Diabetes 34.8% 31.6% 43.6% 47.9% <0.001
Ischemic cardiomyopathy 63.9% 64.3% 54.7% 64.6% 0.024
Glomerular filtration rate (mL/min) 60.5±19.9 58.5±22.3 52.7±20.7 49.6±20.5 <0.001
Systolic blood pressure (mmHg) 124.3±19.1 119±18.1 117.3±19.2 113.8±17.2 <0.001
All-cause mortality 14.6% 17.3% 23.8% 40.2% <0.001
Cardiovascular mortality or rehospitalization for HF 31.4% 33.1% 43.9% 57.3% <0.001
